Arcus Biosciences (RCUS) FY2021 results: revenue $383 million, up 390.9% on the year
Arcus Biosciences, Inc. (RCUS) reported revenue of $383 million for fiscal 2021, the year ended 31 December 2021, up 390.9% on the year before. Net income was $53 million, and diluted earnings per share $0.71. The figures are the company's own, from the 10-K it filed with the SEC on 23 February 2022.
Revenue
$383 million
+390.9% on the year
FY2017FY2021
Operating margin
14.1%
-159.3% a year earlier
FY2017FY2021
Net income
$53 million
FY2017FY2021
Diluted EPS
$0.71
FY2017FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
-256
111
-73.5
Capital expenditure
26.0
3.0
1.9
+766.7%
Free cash flow
-282
108
-75.4
Free cash flow margin
-73.7%
138.7%
-502.6%
Cash from investing
-4.0
-434
59.2
Cash from financing
237
439
1.1
-45.9%
Depreciation and amortisation
4.0
3.0
3.6
+33.3%
Share-based compensation
55.0
22.0
9.0
+150.0%
Buybacks
n/a
n/a
0.1
Diluted shares, weighted
74m
55m
44m
+35.0%
Shares outstanding at period end
71m
65m
46m
+8.7%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
841
502
164
+67.5%
Debt
0.0
0.0
0.0
Operating lease liabilities
117
15.2
n/a
+666.8%
Other liabilities
634
255
39.3
+148.7%
Total liabilities and equity
1,592
772
203
+106.1%
Fixed assets
32.0
10.8
9.3
+196.1%
Investments
533
562
130
-5.0%
Cash and equivalents
148
173
57.9
-14.7%
Other assets
879
26.4
5.5
+3,228.2%
Total assets
1,592
772
203
+106.1%
10-K for the year ended 31 December 2021, filed 23 February 2022: the filing.